CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting attendees, the benefits observed with daraxonrasib among pretreated individuals with metastatic disease exceeded already-lofty expectations.

The overall survival rate for people who got daraxonrasib was 13.2 months, nearly double the 6.7 months people survived on standard chemotherapy alone.

Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.

CHICAGO — The eagerly awaited full dataset from arguably the most pivotal pancreatic cancer trial in decades is now public.Based on the buzz it created among ASCO Annual Meeting…

RASolute 302 findings herald a new standard of care in previously treated patients

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

Daraxonrasib has been hailed as ‘landscape-changing’ for people with the disease

Experts hail daraxonrasib as ‘gamechanger’ for patients with advanced pancreatic cancer

Doctors today hailed a breakthrough in the fight against pancreatic cancer after a new drug was shown to give patients precious extra months of life.

Stay up to date with notifications from The IndependentNotifications can be managed in browser preferences.Jump to contentThank you for registeringPlease refresh the page or…

New research shows a medication called daraxonrasib is helping people with advanced pancreatic cancer live longer.

The drug is called daraxonrasib and it blocks a mutated protein that fuels tumor growth in more than 90% of pancreatic cancer cases — a target that had eluded treatment for…

An experimental drug for advanced pancreatic cancer significantly extended survival in a major clinical trial, offering fresh hope for improved treatment...

The results of a clinical trial of a new drug could signal a breakthrough in treating pancreatic cancer

Un nuovo studio clinico sta attirando grande attenzione nella comunità scientifica internazionale per i risultati ottenuti nel trattamento del tumore al

A groundbreaking daily pill has been shown to double survival time for patients battling the world's deadliest cancer, marking a major advancement in medical research.

La molecola daraxonrasib raddoppia la sopravvivenza contro il tumore al pancreas: i dati promettenti dello studio clinico presentati all'Asco

The drug daraxonrasib nearly doubled the overall survival rates of pancreatic cancer patients. Here's how it works and who can get it.

People with advanced pancreatic cancer taking an experimental daily pill lived nearly twice as long as those receiving chemotherapy infusions

Экспериментальный препарат daraxonrasib компании Revolution Medicines почти вдвое увеличил выживаемость пациентов с метастатическим раком поджелудочной железы…

While the drug is not a cure, researchers say it could meaningfully improve both the length and quality of life for patients with advanced disease. | World News